McGuff Pharmaceuticals, Inc. (MPI) has announced FDA approval of its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. This approval marks a significant milestone for the company, opening new avenues in both the Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) sectors.
Expanding Manufacturing Capabilities
As a CMO/CDMO, MPI supports pharmaceutical companies in bringing new products and formulations to market. The company offers fully integrated drug development and manufacturing services, encompassing formulation development, product stability, regulatory compliance, and clinical trials, all under stringent quality assurance protocols.
The newly approved facility is designed to handle a diverse range of products, including MPI's NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial materials. Its capabilities include sterile fill-and-finish pharmaceutical manufacturing, compounding for solutions, emulsions, and suspensions, and the handling of both sterile and hazardous drugs in vial sizes ranging from 5mL to 100mL. The facility also provides analytical testing and DSCSA-compliant packaging.
Increased Production of Ascorbic Acid Injection
"With this approval, we will increase our production of ASCOR, our FDA-approved Ascorbic Acid Injection (vitamin C injection), ensuring that we meet the growing demands of our customers, both nationally and internationally," stated Ronald M. McGuff, President of MPI. Ascorbic acid injection is commonly used to treat vitamin C deficiency.
Future Outlook
The FDA approval represents a pivotal moment for MPI, enhancing its ability to serve the pharmaceutical industry with comprehensive manufacturing solutions. The company is poised to leverage its expanded capabilities to meet the increasing demand for sterile injectable products and support the development of new therapies.
